ABT-199 was approved for the treatment of chronic lymphoid leukaemia (CLL) in 2016 (NCT01889186)30 and acute myeloid leukaemia (AML) in 2018 (NCT02287233, NCT02203773)31,32, which stimulated the development of other BH3 mimetics that target other anti-apoptotic proteins beyond BCL2 (refs. 27,33). Here, BCL2 is linked to acute myeloid leukemia.